BD Biosciences (BDX) Release: New Stem Cell Tool for Clinical and Lab Professionals  
2/27/2012 12:13:44 PM

February, 2012 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), introduces the BD™ Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto™ II and BD FACSCalibur™ flow cytometers. The Kit is for in vitro diagnostic use and provides a single- tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources.

The BD SCE assay simultaneously enumerates the total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/µL and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). Transplantation of hematopoietic progenitor cells is used increasingly in the treatment of blood disorders, malignancies, and genetic abnormalities. Accurate measure of the CD34 cell count is necessary for dose requirement protocols in stem cell transplantation.

Regression between CD34+ counts derived using the BD SCE Kit and a predicate enumeration assay on the BD FACSCalibur flow cytometer.

The BD SCE Kit is designed for use with a wide selection of sample types, including normal and mobilized peripheral blood, and fresh or frozen leukophoresis, bone marrow, and cord blood. The Kit’s pre-mixed antibodies reduce reagent preparation time to meet productivity demands of clinical labs. The BD SCE assay incorporates BD Trucount™ tubes to determine the absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.

For more information on the BD Stem Cell Enumeration Kit, please visit

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit